The world's second-largest drugmaker says its Xeljanz has been approved in Russia, Argentina, Kuwait, the United Arab Emirates and Switzerland, the first European country to allow sales.
Meanwhile, New York-based Pfizer is asking advisers to European Union medical regulators to reconsider their recommendation not to approve the drug.
The advisers said Xeljanz didn't control progression of the immune disorder enough to outweigh serious side effects seen in some patients. Those include blood and other cancers, perforated intestines, tuberculosis and other infections, decreased infection-fighting cells, headaches and diarrhea.
Xeljanz, the first in a new class of drugs, was launched in the U.S. in November. It has been heavily advertised.
MORE HBJ HEADLINES
Cocktail parties, free breakfasts help Mukilteo workplace win award Bankruptcy filings Briefs: Everett's Keller Williams adds The Gallaher Group Millennium Falcon sans Han Solo passes through Port of Everett Port sees logs headed to Japan for first time in decade Obama’s community college proposal could help small business
Our new comment system is not supported in IE 7. Please upgrade your browser here.